Zoll Medical Corporation (NasdaqGS: ZOLL) announced today that a study
entitled, "Increased CPR Variability During Ground Ambulance Transport
of Patients in Cardiac Arrest” presented by Ben Bobrow, M.D., Medical
Director for the Arizona Department of Health Services, Bureau of
Emergency Medical Services & Trauma System and the Maricopa Medical
Center Resuscitation Science Center, was
named the "Best EMS
Professional Research Presentation” at the National Association of EMS
Physicians (NAEMSP®) 2010 Conference in Phoenix, Arizona.
With data supplied from ZOLL E Series® devices, the study
concluded that healthcare providers are able to perform more consistent
compressions when treating cardiac arrest patients at the scene as
opposed to in the back of a moving ambulance.
This study was conducted with Guardian Medical Transport in Flagstaff,
Arizona, and the Mesa Fire Department in Mesa, Arizona, as part of a
larger Resuscitation Quality Improvement Program. The aim was to
quantify and compare the quality of chest compressions at the scene of a
resuscitation attempt and during transport. The research was undertaken
in response to questions that had been raised about the safety and
efficacy of performing manual chest compressions during the ambulance
transport of patients in cardiac arrest.
Dr. Bobrow stated, "We found an increase in the variability of chest
compression quality for the rate and depth of compressions in our two
EMS agencies during the ground transport of cardiac arrest patients.
Further investigation is needed to determine the causes of the increased
variability along with the optimal timing and method of delivering
manual chest compressions.”
The EMS agencies participating in the project utilized
ZOLL E
Series monitor-defibrillators with an accelerometer to continuously
record chest compression quality during resuscitation both at the scene
and during ambulance transport. The device’s built-in Real CPR Help®,
which provides real-time audiovisual feedback on the correct rate and
depth of chest compressions, was inactivated. ZOLL’s Code Review
software was used to collect data on chest compression quality during
the time a patient was treated at the scene and in transport. The time
during which the patient had spontaneous circulation was excluded from
analysis as CPR would not have been required during those minutes.
Variability was defined as the average of minute-by-minute standard
deviations in depth or rate.
A total of 90 adult cardiac arrest events were electronically recorded,
of which 45 included chest compressions both at the scene and in the
ambulance. Variability in chest compression rate and chest compression
depth was significantly greater during transport compared with at the
scene. Absolute chest compression depth and chest compression rate
tended to be lower during transport. Although not reaching statistical
significance, the percentage of chest compressions in compliance with
AHA 2005 guidelines for depth (1.5-2 in) and rate (100±10
compressions/minute) was nearly double at the scene compared with during
transport.
"We are pleased that ZOLL technology was used in this study,” said
Jonathan A. Rennert, President of ZOLL. "We are very committed to
helping agencies conduct research that may ultimately result in
improving outcomes from cardiac arrest.”
About Sudden Cardiac Arrest
SCA, an abrupt disruption of the heart’s function, which causes a lack
of blood flow to vital organs, claims more than 1 million lives each
year. It is the leading cause of unexpected death in the world and
strikes without warning. Currently, only about 5 percent of victims
survive; 95 percent will die from SCA.
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and
software solutions that help advance emergency care and save lives,
while increasing clinical and operational efficiencies. With products
for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management,
ZOLL provides a comprehensive set of technologies which help clinicians,
EMS and fire professionals, and lay rescuers treat victims needing
resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company
for the past three years, ZOLL develops and manufactures its products in
the United States, in California, Colorado, Illinois, Massachusetts,
Pennsylvania, and Rhode Island. More than 400 direct sales and service
representatives, 1,100 business partners, and 200 independent
representatives serve our customers in over 140 countries around the
globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including
statements regarding the future business of the Company, and other
statements contained herein regarding matters that are not historical
facts, are "forward-looking” statements (as defined in the Private
Securities Litigation Reform Act of 1995). Because such statements are
subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements include, but are
not limited to, those factors discussed in the section entitled "Risk
Factors” in the Company's Quarterly Report on Form 10-Q filed with the
SEC on February 11, 2010. You should not place undue reliance on the
forward looking statements in this press release, and the Company
disavows any obligation to update or supplement those statements in the
event of any changes in the facts, circumstances, or expectations that
underlie those statements.
Copyright © 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill
Road, Chelmsford, MA 01824-4105. ZOLL, E Series and Real CPR Help are
registered trademarks of ZOLL Medical Corporation. All product names are
the property of their respective owners.
